AZ to rework ongoing immuno-oncology trials to "enhance options"
Due to the “strong efficacy” shown by its durvalumab as a treatment for non-small cell lung cancer (NSCLC), AstraZeneca has announced it is to reengineer its clinical trials into the drug in order to “enhance [its] options”, according to company CMO Sean Bohen.
The amendments to its Mystic trial and other related trials investigating durvalumab intend to help explore the firm’s options in first-line NSCLC treatment for a combination of immune-oncology treatments and monotherapy. The Mystic trial was originally designed to evaluate progression-free survival of the drug as a monotherapy and in combination with tremelimumab in patients with PDL1-expressing tumours versus standard-of-care chemotherapy; now redesigned, the trial will also assess overall survival.
First data from the Mystic trial will be released midway through this year, with final results expected sometime in 2018.
Aside from the Mystic trial, the firm is looking to reinforce its regulatory submission of durvalumab in combination with tremelimumab as a first-line NSCLC treatment in China by expanding its Neptune trial in the region with local patients.